Cargando…
Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis
Gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) can detect early stages of hepatocellular carcinoma (HCC). However, the survival benefit of Gd-EOB-DTPA-enhanced MRI in the surveillance of patients with cirrhosis has not yet been determined. We explored whether the int...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953123/ https://www.ncbi.nlm.nih.gov/pubmed/36830919 http://dx.doi.org/10.3390/biomedicines11020382 |
_version_ | 1784893799948877824 |
---|---|
author | Yu, Su Jong Yoo, Jeong-Ju Lee, Dong Ho Kim, Su Jin Cho, Eun Ju Kim, Se Hyung Lee, Jeong-Hoon Kim, Yoon Jun Lee, Jeong Min Lee, Jae Young Yoon, Jung-Hwan |
author_facet | Yu, Su Jong Yoo, Jeong-Ju Lee, Dong Ho Kim, Su Jin Cho, Eun Ju Kim, Se Hyung Lee, Jeong-Hoon Kim, Yoon Jun Lee, Jeong Min Lee, Jae Young Yoon, Jung-Hwan |
author_sort | Yu, Su Jong |
collection | PubMed |
description | Gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) can detect early stages of hepatocellular carcinoma (HCC). However, the survival benefit of Gd-EOB-DTPA-enhanced MRI in the surveillance of patients with cirrhosis has not yet been determined. We explored whether the intermittent replacement of ultrasonography (USG) with Gd-EOB-DTPA-enhanced MRI during HCC surveillance improved the clinical outcomes of patients with cirrhosis. We performed a retrospective cohort study of 421 HCC patients who were newly diagnosed during surveillance. Of these patients, 126 (29.9%) underwent surveillance based on Gd-EOB-DTPA-enhanced MRI and USG (USG+MRI group). The patients (295, 70.1%) who did not undergo MRI during surveillance were referred to as the USG group. In the USG+MRI group, 120 (95.2%) of 126 patients were diagnosed with early-stage HCC, whereas 247 (83.7%) of 295 patients were diagnosed with early-stage HCC in the USG group (P = 0.009). The significantly longer overall survival and time to progression in patients in the USG+MRI group compared to the unmatched cohort USG group was consistently observed by inverse probability weighting and propensity score-matched analysis. Gd-EOB-DTPA-enhanced MRI combined surveillance improved the detection of early-stage HCC and clinical outcomes such as overall survival and the time to progression in patients with cirrhosis. |
format | Online Article Text |
id | pubmed-9953123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99531232023-02-25 Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis Yu, Su Jong Yoo, Jeong-Ju Lee, Dong Ho Kim, Su Jin Cho, Eun Ju Kim, Se Hyung Lee, Jeong-Hoon Kim, Yoon Jun Lee, Jeong Min Lee, Jae Young Yoon, Jung-Hwan Biomedicines Article Gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) can detect early stages of hepatocellular carcinoma (HCC). However, the survival benefit of Gd-EOB-DTPA-enhanced MRI in the surveillance of patients with cirrhosis has not yet been determined. We explored whether the intermittent replacement of ultrasonography (USG) with Gd-EOB-DTPA-enhanced MRI during HCC surveillance improved the clinical outcomes of patients with cirrhosis. We performed a retrospective cohort study of 421 HCC patients who were newly diagnosed during surveillance. Of these patients, 126 (29.9%) underwent surveillance based on Gd-EOB-DTPA-enhanced MRI and USG (USG+MRI group). The patients (295, 70.1%) who did not undergo MRI during surveillance were referred to as the USG group. In the USG+MRI group, 120 (95.2%) of 126 patients were diagnosed with early-stage HCC, whereas 247 (83.7%) of 295 patients were diagnosed with early-stage HCC in the USG group (P = 0.009). The significantly longer overall survival and time to progression in patients in the USG+MRI group compared to the unmatched cohort USG group was consistently observed by inverse probability weighting and propensity score-matched analysis. Gd-EOB-DTPA-enhanced MRI combined surveillance improved the detection of early-stage HCC and clinical outcomes such as overall survival and the time to progression in patients with cirrhosis. MDPI 2023-01-27 /pmc/articles/PMC9953123/ /pubmed/36830919 http://dx.doi.org/10.3390/biomedicines11020382 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yu, Su Jong Yoo, Jeong-Ju Lee, Dong Ho Kim, Su Jin Cho, Eun Ju Kim, Se Hyung Lee, Jeong-Hoon Kim, Yoon Jun Lee, Jeong Min Lee, Jae Young Yoon, Jung-Hwan Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis |
title | Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis |
title_full | Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis |
title_fullStr | Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis |
title_full_unstemmed | Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis |
title_short | Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis |
title_sort | adding mri as a surveillance test for hepatocellular carcinoma in patients with liver cirrhosis can improve prognosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953123/ https://www.ncbi.nlm.nih.gov/pubmed/36830919 http://dx.doi.org/10.3390/biomedicines11020382 |
work_keys_str_mv | AT yusujong addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis AT yoojeongju addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis AT leedongho addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis AT kimsujin addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis AT choeunju addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis AT kimsehyung addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis AT leejeonghoon addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis AT kimyoonjun addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis AT leejeongmin addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis AT leejaeyoung addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis AT yoonjunghwan addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis |